---
title: "China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Commercial’s Nine-Month Net Profit Rises to RMB 1.75 Billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303715107.md"
description: "CR Pharmaceutical Commercial, a subsidiary of China Resources Pharmaceutical Group, reported unaudited consolidated results for the first nine months of 2026. Net profit increased to RMB 1.75 billion from RMB 1.68 billion in the prior year period. Revenue rose to RMB 169.46 billion from RMB 165.1 billion. Operating cash flow turned positive at RMB 327.97 million, compared to an outflow of RMB 36.25 million previously, while financing cash outflow widened significantly."
datetime: "2026-10-30T09:18:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303715107.md)
  - [en](https://longbridge.com/en/news/303715107.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303715107.md)
generator: "portal-rs"
---

# China Resources Pharmaceutical Group Subsidiary CR Pharmaceutical Commercial’s Nine-Month Net Profit Rises to RMB 1.75 Billion

-   CR Pharmaceutical Commercial, a non-wholly-owned subsidiary of China Resources Pharmaceutical Group, released unaudited consolidated results for January-September 2026. \* Net profit rose to RMB 1.75 billion from RMB 1.68 billion a year earlier. \* Revenue increased to RMB 169.46 billion from RMB 165.1 billion. \* Operating cash flow turned positive at RMB 327.97 million, versus an outflow of RMB 36.25 million a year earlier. \* Financing cash outflow widened to RMB 1.77 billion from RMB 510.73 million. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261030-12390204), on October 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

- [China Resources Pharmaceutical Unit Secures Approval for RMB 10 Billion Corporate Bond Issuance](https://longbridge.com/en/news/305661943.md)
- [China Resources Pharmaceutical Completes RMB 800 Million Medium-Term Note Issuance](https://longbridge.com/en/news/302856714.md)
- [NetEase Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into NetEase (NTES)](https://longbridge.com/en/news/306200520.md)
- [PRESS DIGEST-New York Times business news - November 20](https://longbridge.com/en/news/306242079.md)
- [License information for AI chips sent to China released by US House committee](https://longbridge.com/en/news/306167732.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**